Hepatitis C Clinical Trial Landscape
Data updated: May 20, 2026
1,012 clinical trials tracked since 2008
Hepatitis C is a viral infection that attacks the liver and can lead to serious health problems, including liver damage, cirrhosis, liver cancer, and even death. Globally, millions are chronically infected with the Hepatitis C virus. The clinical trial landscape for Hepatitis C features 1,011 registered trials since 2008, with 15 currently active trials in various stages. The majority of active trials are in Phase 2 (5 trials), followed by Phase 4 (6 trials), Phase 1 (3 trials), and Phase 3 (2 trials). This distribution suggests a focus on exploring new therapeutic approaches and evaluating existing treatments in real-world settings. Atea Pharmaceuticals, Inc. is the leading industry sponsor in the active trial landscape, with 2 ongoing trials.
16 active
/
1012 total (since 2008)
3
Phase 1 Active
274 total
5
Phase 2 Active
359 total
2
Phase 3 Active
293 total
7
Phase 4 Active
155 total
Top Industry Sponsors
Sorted by active Active Done Failed
Atea Pharmaceuticals, Inc. 2 3 1
Gilead 0 113 4
Merck 0 76 16
Bristol-Myers Squibb 0 67 11
AbbVie 0 57 2
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT07037277 RECRUITING
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
Atea Pharmaceuticals, Inc. n=880
NCT06868264 ACTIVE NOT RECRUITING
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
Atea Pharmaceuticals, Inc. n=880
NCT02771405 COMPLETED
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
National Hepatology & Tropical Medicine Research Institute n=150
NCT00780910 COMPLETED
Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
Tanabe Pharma Corporation n=109
NCT01753557 COMPLETED
Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C
Tanabe Pharma Corporation n=54
+ 288 more Phase 3 trials — see full database below
Hepatitis C — Trials Started by Year (last 10 years)
2016 68
2017 60
2018 36
2019 28
2020 12
2021 7
2022 6
2023 3
2024 0
2025 4
2026 3
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Atea Pharmaceuticals, Inc. 6
Gilead 117
Merck 92
Bristol-Myers Squibb 78
AbbVie 59
Roche 31
Tibotec Pharmaceuticals, Ireland 26
Boehringer Ingelheim 23
AbbVie (prior sponsor, Abbott) 19
Vertex Pharmaceuticals Incorporated 19
Active Trials by Phase
Phase 1 3
Phase 2 5
Phase 3 2
Phase 4 7
Enrollment Size Distribution
1-50 428
51-200 325
201-500 141
501-1k 50
1k+ 13
All Industry Sponsors
Sorted by active Active Done Failed
Atea Pharmaceuticals, Inc. 2 3 1
Gilead 0 113 4
Merck 0 76 16
Bristol-Myers Squibb 0 67 11
AbbVie 0 57 2
Roche 0 29 2
Tibotec Pharmaceuticals, Ireland 0 26 0
Boehringer Ingelheim 0 21 2
AbbVie (prior sponsor, Abbott) 0 19 0
Vertex Pharmaceuticals Incorporated 0 13 6
Janssen R&D Ireland 0 15 2
GSK 0 11 2
Abbott 0 12 0
Tanabe Pharma Corporation 0 10 0
Sunshine Lake Pharma Co., Ltd. 0 10 0
NCT07037277 RECRUITING
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
Atea Pharmaceuticals, Inc. n=880
NCT06868264 ACTIVE NOT RECRUITING
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
Atea Pharmaceuticals, Inc. n=880
NCT02771405 COMPLETED
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
National Hepatology & Tropical Medicine Research Institute n=150
NCT00780910 COMPLETED
Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
Tanabe Pharma Corporation n=109
NCT01753557 COMPLETED
Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C
Tanabe Pharma Corporation n=54
NCT00780416 COMPLETED
Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C
Tanabe Pharma Corporation n=189
NCT00781274 COMPLETED
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy
Tanabe Pharma Corporation n=32
NCT01753570 COMPLETED
Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)
Tanabe Pharma Corporation n=74
NCT01468584 COMPLETED
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients
Tanabe Pharma Corporation n=10
NCT01466192 COMPLETED
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients
Tanabe Pharma Corporation n=108
NCT01718301 TERMINATED
HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin
Anna Cruceta n=108
NCT02890719 WITHDRAWN
Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.
Fundacion Clinic per a la Recerca Biomédica
NCT05395416 COMPLETED
Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C
Sunshine Lake Pharma Co., Ltd. n=514
NCT04903626 COMPLETED
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
AbbVie n=286
NCT04885855 COMPLETED
8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C
Muhammad Radzi Abu Hassan n=322
NCT03099135 TERMINATED
A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection
Janssen Research & Development, LLC n=24
NCT05465434 COMPLETED
Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HCV Patient Receiving Direct Acting Anti-viral Therapy.
Tanta University n=50
NCT03801707 COMPLETED
Utilization of Hepatitis C Positive Kidneys in Negative Recipients
Ohio State University n=54
NCT01866930 TERMINATED
Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV
Bristol-Myers Squibb n=453
NCT03067129 COMPLETED
A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection
AbbVie n=129
NCT02596880 COMPLETED
Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics
Tehran University of Medical Sciences n=100
NCT02219490 COMPLETED
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
AbbVie n=1,596
NCT03496233 COMPLETED
Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo n=75
NCT05616598 COMPLETED
Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters
Benha University n=200
NCT02660905 COMPLETED
HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection
Ottawa Hospital Research Institute n=25
NCT02634008 COMPLETED
Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P
Kirby Institute n=83
NCT02167945 COMPLETED
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
AbbVie n=615
NCT02939989 COMPLETED
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
AbbVie n=33
NCT04112303 COMPLETED
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis
Gilead Sciences n=37
NCT04382937 COMPLETED
Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection
PharmaEssentia n=222
NCT02625909 COMPLETED
Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.
Kirby Institute n=222
NCT01482767 COMPLETED
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
National Institute of Allergy and Infectious Diseases (NIAID) n=262
NCT04211909 COMPLETED
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection
Gilead Sciences n=87
NCT02486406 COMPLETED
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
AbbVie n=64
NCT02455167 TERMINATED
Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis
University of Colorado, Denver n=9
NCT02555943 COMPLETED
DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)
Humanity and Health Research Centre n=23
NCT01715415 COMPLETED
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
AbbVie (prior sponsor, Abbott) n=395
NCT02640157 COMPLETED
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
AbbVie n=506
NCT02582632 COMPLETED
A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults
AbbVie n=166
NCT02023112 COMPLETED
Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection
AbbVie n=171
NCT02243293 COMPLETED
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
AbbVie n=694
NCT02966795 COMPLETED
A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
AbbVie n=84
NCT02247401 COMPLETED
Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
AbbVie n=160
NCT02723084 COMPLETED
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection
AbbVie n=136
NCT02640482 COMPLETED
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
AbbVie n=304
NCT02707952 COMPLETED
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection
AbbVie n=295
NCT02738138 COMPLETED
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
AbbVie n=153
NCT02604017 COMPLETED
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection
AbbVie n=703
NCT02642432 COMPLETED
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis
AbbVie n=146
NCT02692703 COMPLETED
A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)
AbbVie n=100
NCT02636595 COMPLETED
The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)
AbbVie n=121
NCT01704755 COMPLETED
A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
AbbVie (prior sponsor, Abbott) n=381
NCT01939197 COMPLETED
A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection
AbbVie n=318
NCT01716585 COMPLETED
A Study to Evaluate Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott) n=636
NCT01674725 COMPLETED
A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C
AbbVie (prior sponsor, Abbott) n=187
NCT02219503 COMPLETED
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis
AbbVie n=60
NCT01767116 COMPLETED
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
AbbVie (prior sponsor, Abbott) n=419
NCT01833533 COMPLETED
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
AbbVie n=305
NCT03480932 COMPLETED
Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]
Johns Hopkins Bloomberg School of Public Health n=150
NCT00755950 TERMINATED
Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis
University of Maryland, Baltimore n=70
NCT03883698 COMPLETED
Safety of Sofosbuvir in People With Advanced Kidney Failure
Sanjay Gandhi Postgraduate Institute of Medical Sciences n=30
NCT00758043 COMPLETED
A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response
Vertex Pharmaceuticals Incorporated n=540
NCT03020082 COMPLETED
Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III
Ascletis Pharmaceuticals Co., Ltd. n=141
NCT01023035 COMPLETED
Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)
Merck Sharp & Dohme LLC n=687
NCT01425203 COMPLETED
The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)
Merck Sharp & Dohme LLC n=238
NCT00910624 COMPLETED
Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)
Merck Sharp & Dohme LLC n=168
NCT02105662 COMPLETED
An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)
Merck Sharp & Dohme LLC n=218
NCT02105701 COMPLETED
Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)
Merck Sharp & Dohme LLC n=420
NCT04155515 COMPLETED
A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. n=370
NCT01590225 WITHDRAWN
Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)
Merck Sharp & Dohme LLC
NCT02825212 COMPLETED
Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia
Icahn School of Medicine at Mount Sinai n=10
NCT03578640 COMPLETED
Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4
King Fahad Medical City n=30
NCT02170727 COMPLETED
A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
Bristol-Myers Squibb n=199
NCT02973503 COMPLETED
Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis
University Hospital, Clermont-Ferrand n=117
NCT02441283 COMPLETED
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
AbbVie n=384
NCT01995266 COMPLETED
Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual
Bristol-Myers Squibb n=218
NCT01741545 COMPLETED
Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia
Bristol-Myers Squibb n=71
NCT03362814 COMPLETED
Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.
Ascletis Pharmaceuticals Co., Ltd. n=425
NCT03089944 COMPLETED
A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis
AbbVie n=343
NCT04387526 COMPLETED
Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4
Beni-Suef University n=946
NCT03487107 COMPLETED
Phase 3 Study of Yimitasvir Phosphate Capsules
Sunshine Lake Pharma Co., Ltd. n=362
NCT03219216 COMPLETED
A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection
AbbVie n=100
NCT02613871 COMPLETED
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection
Gilead Sciences n=111
NCT02021656 COMPLETED
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection
Gilead Sciences n=384
NCT03092375 COMPLETED
Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects
University of Florida n=177
NCT03222583 COMPLETED
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection
AbbVie n=546
NCT03117569 COMPLETED
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
Kirby Institute n=380
NCT02609659 COMPLETED
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection
AbbVie n=105
NCT02105688 COMPLETED
An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)
Merck Sharp & Dohme LLC n=301
NCT01762761 COMPLETED
Eltrombopag Phase III Study In Chinese Chronic ITP Patients
Novartis Pharmaceuticals n=155
NCT03235349 COMPLETED
Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection
AbbVie n=160
NCT01821625 TERMINATED
Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C
University of Texas Southwestern Medical Center n=7
NCT03212521 COMPLETED
Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1
AbbVie n=230
NCT01598090 COMPLETED
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
Bristol-Myers Squibb n=881
NCT02600325 COMPLETED
Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV
Erasmus Medical Center n=80
NCT02115321 COMPLETED
Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)
Merck Sharp & Dohme LLC n=40
NCT03995485 COMPLETED
KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C
Kawin Technology Share-holding Co., Ltd. n=371
NCT03118843 COMPLETED
Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study
Gilead Sciences n=31
NCT03074331 COMPLETED
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection
Gilead Sciences n=130
NCT02639338 COMPLETED
Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis
Gilead Sciences n=220
NCT02607800 COMPLETED
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy
Gilead Sciences n=943
NCT02639247 COMPLETED
Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor
Gilead Sciences n=333
NCT02607735 COMPLETED
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
Gilead Sciences n=416
NCT03069365 COMPLETED
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment
AbbVie n=101
NCT02996682 COMPLETED
Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis
Gilead Sciences n=102
NCT03369327 COMPLETED
Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus
Tehran University of Medical Sciences n=232
NCT03833362 COMPLETED
Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)
R-Pharm n=420
NCT02251990 COMPLETED
Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)
Merck Sharp & Dohme LLC n=489
NCT03186365 COMPLETED
8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis
Kaohsiung Medical University Chung-Ho Memorial Hospital n=82
NCT03004625 COMPLETED
Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV
Kaohsiung Medical University Chung-Ho Memorial Hospital n=70
NCT02671500 COMPLETED
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV
Gilead Sciences n=375
NCT02073656 COMPLETED
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
Gilead Sciences n=335
NCT01701401 COMPLETED
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV
Gilead Sciences n=870
NCT02738333 COMPLETED
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection
Gilead Sciences n=239
NCT02600351 TERMINATED
Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies
Gilead Sciences n=87
NCT02472886 COMPLETED
Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection
Gilead Sciences n=153
NCT02722837 COMPLETED
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection
Gilead Sciences n=119
NCT01768286 COMPLETED
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection
Gilead Sciences n=441
NCT02480712 COMPLETED
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Gilead Sciences n=107
NCT01851330 COMPLETED
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)
Gilead Sciences n=647
NCT02346721 COMPLETED
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
Gilead Sciences n=111
NCT02487030 COMPLETED
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection
Gilead Sciences n=255
NCT02201953 COMPLETED
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection
Gilead Sciences n=558
NCT01975675 COMPLETED
Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection
Gilead Sciences n=341
NCT02201940 COMPLETED
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection
Gilead Sciences n=741
NCT02201901 COMPLETED
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Gilead Sciences n=268
NCT02220998 COMPLETED
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection
Gilead Sciences n=269
NCT02707601 COMPLETED
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
Gilead Sciences n=150
NCT02822794 COMPLETED
Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen
Gilead Sciences n=117
NCT02597166 COMPLETED
Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection
University Health Network, Toronto n=14
NCT01370642 COMPLETED
Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)
Merck Sharp & Dohme LLC n=294
NCT01405560 COMPLETED
Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)
Merck Sharp & Dohme LLC n=42
NCT01405937 COMPLETED
Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)
Merck Sharp & Dohme LLC n=51
NCT00678587 TERMINATED
Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
GlaxoSmithKline n=292
NCT02517528 COMPLETED
ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis
AbbVie n=104
NCT02252016 COMPLETED
Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)
Merck Sharp & Dohme LLC n=159
NCT02358044 COMPLETED
Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)
Merck Sharp & Dohme LLC n=257
NCT02105467 COMPLETED
Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)
Merck Sharp & Dohme LLC n=421
NCT02092350 COMPLETED
Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)
Merck Sharp & Dohme LLC n=237
NCT02203149 COMPLETED
Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)
Merck Sharp & Dohme LLC n=399
NCT03490097 COMPLETED
Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination
Ain Shams University n=100
NCT01544920 COMPLETED
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
Merck Sharp & Dohme LLC n=737
NCT01390844 COMPLETED
Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)
Merck Sharp & Dohme LLC n=282
NCT02103439 COMPLETED
An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients
Biocad n=140
NCT01889433 COMPLETED
An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C
Biocad n=170
NCT01945294 COMPLETED
Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)
Merck Sharp & Dohme LLC n=257
NCT02023099 COMPLETED
Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
AbbVie n=363
NCT01854528 COMPLETED
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults
AbbVie n=148
NCT01854697 COMPLETED
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before
AbbVie n=311
NCT03080415 COMPLETED
Treatment of Egyptian Hepatitis C Genotype 4 Infected Children (and Adolescents) With Combined Sofosbuvir & Daclatasvir
Yassin Abdelghaffar Charity Center for Liver Disease and Research n=40
NCT02673489 COMPLETED
A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection
Bristol-Myers Squibb n=106
NCT02705534 COMPLETED
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
Tehran University of Medical Sciences n=50
NCT02473211 COMPLETED
SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients
Humanity and Health Research Centre n=106
NCT02576314 COMPLETED
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients
Humanity and Health Research Centre n=48
NCT02060058 COMPLETED
Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy
Kaohsiung Medical University Chung-Ho Memorial Hospital n=12
NCT02021643 COMPLETED
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection
Gilead Sciences n=687
NCT01707849 COMPLETED
The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation
Hospital Vall d'Hebron n=18
NCT02465203 TERMINATED
3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study
Novartis Pharmaceuticals n=105
NCT03186313 COMPLETED
A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection
Egyptian Liver Hospital n=72
NCT02504099 TERMINATED
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma
AbbVie n=3
NCT01773070 COMPLETED
A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study
AbbVie (prior sponsor, Abbott) n=478
NCT02487199 COMPLETED
Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease
AbbVie n=18
NCT02207088 COMPLETED
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
AbbVie n=68
NCT02517515 COMPLETED
ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
AbbVie n=650
NCT02651194 COMPLETED
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection
AbbVie n=104
NCT02442284 COMPLETED
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
AbbVie n=99
NCT02476617 COMPLETED
Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults
AbbVie n=25
NCT02446717 COMPLETED
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy
AbbVie n=141
NCT02265237 COMPLETED
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
AbbVie n=184
NCT02442271 COMPLETED
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil
AbbVie n=222
NCT02099604 WITHDRAWN
Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C
ANRS, Emerging Infectious Diseases
NCT02219477 COMPLETED
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
AbbVie n=36
NCT01567735 COMPLETED
A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients
Janssen R&D Ireland n=107
NCT01962441 COMPLETED
SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection
Gilead Sciences n=601
NCT01890200 WITHDRAWN
The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)
TCM Biotech International Corp.
NCT03090035 COMPLETED
Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment
Sheikh Zayed Medical College n=98
NCT02496078 COMPLETED
A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection
Bristol-Myers Squibb n=207
NCT01349465 COMPLETED
3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection
Janssen R&D Ireland n=249
NCT00708500 COMPLETED
Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)
Merck Sharp & Dohme LLC n=404
NCT00845065 COMPLETED
Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)
Merck Sharp & Dohme LLC n=202
NCT00705432 COMPLETED
Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)
Merck Sharp & Dohme LLC n=1,472
NCT01804829 COMPLETED
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
Biotest Pharmaceuticals Corporation n=80
NCT02032875 COMPLETED
Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant
Bristol-Myers Squibb n=116
NCT02319031 COMPLETED
Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis
Bristol-Myers Squibb n=53
NCT00927290 TERMINATED
Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance
French National Agency for Research on AIDS and Viral Hepatitis n=40
NCT01446250 TERMINATED
Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1
Debiopharm International SA n=8
NCT02319200 TERMINATED
Primary Prevention Hepatocellular Carcinoma by Metformin
Assistance Publique - Hôpitaux de Paris n=11
NCT01890083 TERMINATED
A Health Intervention to Prevent Depression Hepatitis C Patients
University of Texas Southwestern Medical Center n=1
NCT02399345 COMPLETED
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults
AbbVie n=10
NCT02806362 WITHDRAWN
Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
AbbVie
NCT02810275 COMPLETED
Folinic Acid: Supplementation and Therapy
Hospital de Clinicas de Porto Alegre n=69
NCT02250807 COMPLETED
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection
Janssen R&D Ireland n=40
NCT01296971 WITHDRAWN
A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)
Hoffmann-La Roche
NCT02053519 COMPLETED
Can Vitamin D Supplementation Improve Hepatitis C Cure Rates
University of Dundee n=72
NCT02074514 COMPLETED
Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection
Gilead Sciences n=117
NCT02483156 COMPLETED
Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV Infection
Egyptian Liver Hospital n=80
NCT01318694 COMPLETED
Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants
Debiopharm International SA n=1,081
NCT01846832 COMPLETED
A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection
Janssen-Cilag International NV n=232
NCT01358864 COMPLETED
Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)
Boehringer Ingelheim n=678
NCT01399619 COMPLETED
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Boehringer Ingelheim n=310
NCT02753699 COMPLETED
Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients
Debiopharm International SA n=723
NCT01500616 COMPLETED
Telaprevir Open-Label Study in Co-Infected Patients
Janssen-Cilag International NV n=122
NCT02478229 TERMINATED
Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)
University Health Network, Toronto n=1
NCT01500772 TERMINATED
Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C
Debiopharm International SA n=6
NCT01571583 COMPLETED
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Janssen-Cilag International NV n=74
NCT01330316 COMPLETED
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Boehringer Ingelheim n=119
NCT02216422 COMPLETED
A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection
AbbVie n=36
NCT01492426 COMPLETED
Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
Bristol-Myers Squibb n=605
NCT01513941 COMPLETED
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Janssen-Cilag International NV n=163
NCT01485991 COMPLETED
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Janssen R&D Ireland n=771
NCT01732796 COMPLETED
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Boehringer Ingelheim n=470
NCT02114177 COMPLETED
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis
Janssen Infectious Diseases BVBA n=310
NCT02114151 COMPLETED
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
Janssen Infectious Diseases BVBA n=103
NCT01323244 COMPLETED
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Janssen R&D Ireland n=142
NCT01728324 COMPLETED
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Boehringer Ingelheim n=496
NCT01471574 COMPLETED
Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus
Bristol-Myers Squibb n=549
NCT01625338 COMPLETED
Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
Gilead Sciences n=534
NCT01979939 COMPLETED
UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects
Bristol-Myers Squibb n=416
NCT02032888 COMPLETED
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
Bristol-Myers Squibb n=238
NCT02282709 COMPLETED
Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients
Foundation for Liver Research n=12
NCT02204475 WITHDRAWN
Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)
Merck Sharp & Dohme LLC
NCT01389323 COMPLETED
BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C
Bristol-Myers Squibb n=448
NCT01448044 COMPLETED
Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C
Bristol-Myers Squibb n=152
NCT01973049 COMPLETED
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
Bristol-Myers Squibb n=202
NCT01497834 COMPLETED
A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients
Bristol-Myers Squibb n=224
NCT01581203 COMPLETED
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Bristol-Myers Squibb n=748
NCT01616524 COMPLETED
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Bristol-Myers Squibb n=880
NCT01573351 COMPLETED
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Bristol-Myers Squibb n=398
NCT01718158 COMPLETED
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
Bristol-Myers Squibb n=444
NCT01718145 COMPLETED
A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects
Bristol-Myers Squibb n=258
NCT02032901 COMPLETED
Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV
Bristol-Myers Squibb n=173
NCT01903278 COMPLETED
Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C
Beijing Kawin Technology Share-Holding Co., Ltd. n=719
NCT01585584 COMPLETED
Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment
University of Calgary n=11
NCT01297270 COMPLETED
Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)
Boehringer Ingelheim n=658
NCT01343888 COMPLETED
Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)
Boehringer Ingelheim n=656
NCT02123654 COMPLETED
UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C
Bristol-Myers Squibb n=297
NCT01641666 WITHDRAWN
Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)
Merck Sharp & Dohme LLC
NCT01740089 COMPLETED
Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C
Biocad n=150
NCT01725529 COMPLETED
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
Janssen R&D Ireland n=457
NCT01579474 COMPLETED
Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial
Boehringer Ingelheim n=131
NCT01459913 TERMINATED
Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype
Vertex Pharmaceuticals Incorporated n=239
NCT01896193 COMPLETED
Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection
Gilead Sciences n=127
NCT01838590 COMPLETED
Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
Gilead Sciences n=103
NCT01783678 COMPLETED
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
Gilead Sciences n=275
NCT01226771 COMPLETED
Ribavirin Loading Dose or Priming and Concentration Targeting for HCV Genotype 1
Göteborg University n=105
NCT01910636 COMPLETED
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection
Gilead Sciences n=153
NCT01467479 TERMINATED
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Vertex Pharmaceuticals Incorporated n=185
NCT01871662 WITHDRAWN
Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C
Rottapharm
NCT01498068 COMPLETED
Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C
Janssen-Cilag International NV n=36
NCT01754974 COMPLETED
Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C
Bristol-Myers Squibb n=40
NCT01667731 COMPLETED
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
Gilead Sciences n=224
NCT01433887 COMPLETED
Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6
Third Affiliated Hospital, Sun Yat-Sen University n=535
NCT01263860 COMPLETED
A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients
Third Affiliated Hospital, Sun Yat-Sen University n=242
NCT01479868 COMPLETED
A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1
Janssen R&D Ireland n=109
NCT01682720 COMPLETED
Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Gilead Sciences n=421
NCT01581398 COMPLETED
Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients
Xiamen Amoytop Biotech Co., Ltd. n=770
NCT01197157 COMPLETED
Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients
National Liver Institute, Egypt n=200
NCT00627926 COMPLETED
A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)
Vertex Pharmaceuticals Incorporated n=1,095
NCT00662220 TERMINATED
High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4
Foundation for Liver Research n=110
NCT01290679 COMPLETED
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants
Janssen R&D Ireland n=393
NCT01289782 COMPLETED
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients
Janssen R&D Ireland n=395
NCT01241760 COMPLETED
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection
Janssen Infectious Diseases BVBA n=744
NCT01604850 COMPLETED
Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)
Gilead Sciences n=202
NCT01542788 COMPLETED
Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon
Gilead Sciences n=278
NCT01890772 WITHDRAWN
Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1
Timothy Morgan, MD
NCT01641640 COMPLETED
Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection
Gilead Sciences n=328
NCT01366638 COMPLETED
A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection
Janssen Pharmaceutical K.K. n=79
NCT01281839 COMPLETED
An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy
Janssen R&D Ireland n=394
NCT01290731 COMPLETED
A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy
Janssen Pharmaceutical K.K. n=49
NCT01288209 COMPLETED
A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy
Janssen Pharmaceutical K.K. n=106
NCT01858961 WITHDRAWN
Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients
Boehringer Ingelheim
NCT00703118 COMPLETED
A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment
Tibotec BVBA n=663
NCT01292239 COMPLETED
A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients
Janssen Pharmaceutical K.K. n=183
NCT00996216 COMPLETED
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
GlaxoSmithKline n=27
NCT01997203 TERMINATED
Long Term Vitamin D Therapy in HCV Treated Patients
Dr. Nadia AbdelAaty AbdelKader n=100
NCT01797848 WITHDRAWN
Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients
Bristol-Myers Squibb
NCT01258686 COMPLETED
Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy
Bukwang Pharmaceutical n=53
NCT00800735 COMPLETED
A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols
Hoffmann-La Roche n=30
NCT01419899 COMPLETED
Increasing Viral Testing in the Emergency Department
Rhode Island Hospital n=398
NCT00623428 COMPLETED
A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response
Hoffmann-La Roche n=235
NCT01054573 COMPLETED
VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo
Janssen Infectious Diseases BVBA n=90
NCT01276756 COMPLETED
Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)
Cairo University n=100
NCT01608737 WITHDRAWN
A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection
Boehringer Ingelheim
NCT00657397 COMPLETED
Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices
French National Agency for Research on AIDS and Viral Hepatitis n=197
NCT00778843 COMPLETED
Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C
Catalysis SL n=60
NCT01517308 WITHDRAWN
24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C
Federico II University
NCT01447394 WITHDRAWN
Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C
Bristol-Myers Squibb
NCT01006031 COMPLETED
Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4
Sociedad Andaluza de Enfermedades Infecciosas n=25
NCT01095445 TERMINATED
EXtended Therapy in Hepatitis C Genotype 3 Infected Patients
University Health Network, Toronto n=2
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only